Where Will Palo Alto Networks Stock Be in 5 Years?
You know those companies that just refuse to slow down…
Buy
76
BSX Quote, Financials, Valuation and Earnings
Last price:
$106.17
Seasonality move
:
3.45%
Day range:
$105.22 - $106.67
52-week range:
$71.88 - $107.17
Dividend yield:
0%
P/E ratio:
77.50x
P/S ratio:
9.00x
P/B ratio:
7.07x
Volume:
6.8M
Avg. volume:
7.1M
1-year change:
40.38%
Market cap:
$157.1B
Revenue:
$16.7B
EPS (TTM):
$1.37
Analysts' Opinion
-
Consensus RatingBoston Scientific has received a consensus rating of Buy. The company's average rating is a Buy based on 23 Buy ratings, 3 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $116.96, Boston Scientific has an estimated upside of 10.17% from its current price of $106.17.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $86.20 representing 100% downside risk from its current price of $106.17.
Fair Value
-
According to the consensus of 26 analysts, Boston Scientific has 10.17% upside to fair value with a price target of $116.96 per share.
BSX vs. S&P 500
-
Over the past 5 trading days, Boston Scientific has underperformed the S&P 500 by -1.8% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Boston Scientific does not have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Boston Scientific has grown year-over-year revenues for 17 quarters straight. In the most recent quarter Boston Scientific reported revenues of $4.7B.
Earnings Growth
-
Boston Scientific has grown year-over-year earnings for 2 quarters straight. In the most recent quarter Boston Scientific reported earnings per share of $0.45.
Enterprise value:
167.8B
EV / Invested capital:
4.99x
Price / LTM sales:
9.00x
EV / EBIT:
59.98x
EV / Revenue:
9.56x
PEG ratio (5yr expected):
5.12x
EV / Free cash flow:
61.61x
Price / Operating cash flow:
58.04x
Enterprise value / EBITDA:
41.05x
Gross Profit (TTM):
$12.1B
Return On Assets:
5.31%
Net Income Margin (TTM):
11.58%
Return On Equity:
9.57%
Return On Invested Capital:
6.35%
Operating Margin:
20.09%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-03-31 | 2024-03-31 | 2025-03-31 | 2024-03-31 | 2025-03-31 | |
| Income Statement | ||||||
| Revenue | $13B | $14.7B | $17.6B | $3.9B | $4.7B | |
| Gross Profit | $9B | $10.2B | $12.1B | $2.6B | $3.2B | |
| Operating Income | $2.1B | $2.5B | $3.2B | $693M | $937M | |
| EBITDA | $2.8B | $3.6B | $4.1B | $981M | $1.2B | |
| Diluted EPS | $0.59 | $1.19 | $1.37 | $0.33 | $0.45 | |
| Period Ending | 2021-03-31 | 2022-03-31 | 2023-03-31 | 2024-03-31 | 2025-03-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $6.1B | $5.1B | $5.7B | $8.2B | $7.3B | |
| Total Assets | $30.9B | $32.3B | $32.9B | $36.7B | $40.1B | |
| Current Liabilities | $3.4B | $4.3B | $4.1B | $4.9B | $5.1B | |
| Total Liabilities | $15.2B | $15.6B | $14.8B | $16.5B | $17.7B | |
| Total Equity | $15.7B | $16.7B | $18.1B | $20.2B | $22.4B | |
| Total Debt | $9.1B | $9.3B | $9B | $10.6B | $11.2B | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-03-31 | 2024-03-31 | 2025-03-31 | 2024-03-31 | 2025-03-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | $1.8B | $2.5B | $3.8B | $164M | $541M | |
| Cash From Investing | -$921M | -$2.4B | -$5.9B | -$285M | -$500M | |
| Cash From Financing | -$611M | $1.6B | $478M | $1.6B | $233M | |
| Free Cash Flow | $1.2B | $1.6B | $2.7B | -$81M | $277M | |
BSX
Sector
Market Cap
$157.1B
$34.7M
Price % of 52-Week High
99.07%
42.33%
Dividend Yield
0%
0%
Shareholder Yield
--
-0.66%
1-Year Price Total Return
40.38%
-41.18%
Beta (5-Year)
0.685
0.653
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Buy
Level
$105.49
200-day SMA
Buy
Level
$92.57
Bollinger Bands (100)
Buy
Level
95.44 - 105.06
Chaikin Money Flow
Buy
Level
1.1B
20-day SMA
Buy
Level
$104.29
Relative Strength Index (RSI14)
Buy
Level
62.74
ADX Line
Buy
Level
20.54
Williams %R
Sell
Level
-16.9816
50-day SMA
Buy
Level
$100.45
MACD (12, 26)
Buy
Level
1.54
25-day Aroon Oscillator
Buy
Level
84
On Balance Volume
Neutral
Level
798.1M
Financial Scores
Buy
Altman Z-Score
(Annual)
Level (5.2964)
Buy
CA Score
(Annual)
Level (0.2571)
Buy
Beneish M-Score
(Annual)
Level (-2.5162)
Buy
Momentum Score
Level (9)
Buy
Ohlson Score
Level (-1.6986)
Buy
Piotroski F Score
(Annual)
Level (7)
Buy
Quality Ratio Score
Level (5)
Buy
Fundamental Score
Level (8)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Boston Scientific produces less invasive medical devices that are inserted into the human body through small openings or cuts. It manufactures products for use in angioplasty, blood clot filtration, kidney stone management, cardiac rhythm management, catheter-directed ultrasound imaging, upper gastrointestinal tract diagnostics, interventional oncology, neuromodulation for chronic pain, and treatment of incontinence. The firm markets its devices to healthcare professionals and institutions globally. Foreign sales account for nearly half of the firm's total sales.
Stock Forecast FAQ
In the current month, BSX has received 23 Buy ratings 3 Hold ratings, and 0 Sell ratings. The BSX average analyst price target in the past 3 months is $116.96.
-
Where Will Boston Scientific Stock Be In 1 Year?
According to analysts, the consensus estimate is that Boston Scientific share price will rise to $116.96 per share over the next 12 months.
-
What Do Analysts Say About Boston Scientific?
Analysts are divided on their view about Boston Scientific share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Boston Scientific is a Sell and believe this share price will drop from its current level to $86.20.
-
What Is Boston Scientific's Price Target?
The price target for Boston Scientific over the next 1-year time period is forecast to be $116.96 according to 26 Wall Street analysts, 23 of them rate the stock a Buy, 0 rate the stock a Sell, and 3 analysts rate the stock a Hold.
-
Is BSX A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Boston Scientific is a Buy. 23 of 26 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of BSX?
You can purchase shares of Boston Scientific via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, tastytrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Boston Scientific shares.
-
What Is The Boston Scientific Share Price Today?
Boston Scientific was last trading at $106.17 per share. This represents the most recent stock quote for Boston Scientific. Yesterday, Boston Scientific closed at $106.17 per share.
-
How To Buy Boston Scientific Stock Online?
In order to purchase Boston Scientific stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
UPS Stock Forecast: Is the 6.9% Dividend Too Good to Be True?
Parcel delivery giant UPS (NYSE:UPS) has seen its fair share…
Where Will Coinbase Stock Be in 5 Years?
If you’ve been anywhere near the crypto world over the…
Stock Ideas
Buy
70
Is MSFT Stock a Buy?
Market Cap: $3.4T
P/E Ratio: 39x
Buy
68
Is NVDA Stock a Buy?
Market Cap: $3.3T
P/E Ratio: 46x
Sell
39
Is AAPL Stock a Buy?
Market Cap: $3T
P/E Ratio: 33x
Alerts
Buy
84
SBET alert for May 28
SharpLink Gaming [SBET] is up 454.46% over the past day.
Buy
58
TNXP alert for May 28
Tonix Pharmaceuticals Holding [TNXP] is up 27.51% over the past day.
Sell
37
ATS alert for May 28
ATS [ATS] is up 19.57% over the past day.
